Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib

BACKGROUND: Ibrutinib is a Bruton’s tyrosine kinase inhibitor used in the treatment of hematological malignancies. The most common cardiotoxicity associated with ibrutinib is atrial arrhythmia (atrial fibrillation and flutter). It is known that patients with cardiovascular disease (CVD) are at an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Avalon, Juan Carlo, Fuqua, Jacob, Miller, Tyler, Deskins, Seth, Wakefield, Chelby, King, Austin, Inderbitzin-Brooks, Sonya, Bianco, Christopher, Veltri, Lauren, Fang, Wei, Craig, Michael, Kanate, Abraham, Ross, Kelly, Malla, Midhun, Patel, Brijesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603583/
https://www.ncbi.nlm.nih.gov/pubmed/34798905
http://dx.doi.org/10.1186/s40959-021-00125-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603583/
https://www.ncbi.nlm.nih.gov/pubmed/34798905
http://dx.doi.org/10.1186/s40959-021-00125-8

Ejemplares similares